Effects of pioglitazone on macrovascular events in patients with type 2 diabetes mellitus at high risk of stroke: the PROFIT-J study.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Journal of atherosclerosis and thrombosis

• Publication date

  2014-06-25

• Fields of study

  Medicine

• Identifiers
  DOI 10.5551/JAT.21626PMID 24477028
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Incidence and Risk Factors

  2015cited by this paper
• International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values

  2012cited by this paper
• Low-Dose Aspirin for Primary Prevention of Atherosclerotic Events in Patients With Type 2 Diabetes

  2012cited by this paper
• High‐density lipoprotein‐cholesterol and not HbA1c was directly related to cardiovascular outcome in PROactive

  2011cited by this paper
• Cardiovascular risk and thiazolidinediones—what do meta‐analyses really tell us?

  2010cited by this paper
• Prognostic Value of Gated Myocardial Perfusion Imaging for Asymptomatic Patients With Type 2 Diabetes

  2010cited by this paper
• The effect of intensive glucose control on all-cause and cardiovascular mortality, myocardial infarction and stroke in persons with type 2 diabetes mellitus: a systematic review and meta-analysis

  2010cited by this paper
• Long-term effects of pioglitazone on carotid atherosclerosis in Japanese patients with type 2 diabetes without a recent history of macrovascular morbidity.

  2010cited by this paper
• Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells

  2010cited by this paper
• Relationship Between CarotidIntima-Media Thickness and Silent Cerebral Infarction in Japanese Subjects With Type 2 Diabetes

  2009cited by this paper
• 10-year follow-up of intensive glucose control in type 2 diabetes.

  2008cited by this paper
• Is the Combination of Sulfonylureas and Metformin Associated With an Increased Risk of Cardiovascular Disease or All-Cause Mortality?

  2008cited by this paper
• Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.

  2008cited by this paper
• Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

  2007cited by this paper
• Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC)

  2007cited by this paper
• Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.

  2007cited by this paper
• Standardizing display conditions of diffusion-weighted images using concurrent b0 images: a multi-vendor multi-institutional study.

  2007cited by this paper
• Effects of Pioglitazone in Patients With Type 2 Diabetes With or Without Previous Stroke: Results From PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04)

  2007cited by this paper
• Incidence and Risk Factors for Stroke in Type 2 Diabetic Patients: The DAI Study

  2007cited by this paper
• Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial.

  2006cited by this paper
• A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia.

  2005cited by this paper
• Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

  2005cited by this paper
• Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.

  2005cited by this paper
• Effects of Angiotensin Converting Enzyme Inhibition in Patients With Stable Coronary Artery Disease: The Prevention of Events With Angiotensin Converting Enzyme Inhibition (PEACE) Trial: The PEACE Study Investigators

  2005cited by this paper
• Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies.

  2004cited by this paper
• Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice.

  2000cited by this paper
• The causes and risk of stroke in patients with asymptomatic internal-carotid-artery stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators.

  2000cited by this paper
• Peroxisome proliferator–activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor–deficient mice

  2000cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)

  1998cited by this paper
• Diabetes and Cardiovascular Disease in a Prospective Population Survey in Japan: The Hisayama Study

  1996cited by this paper
• Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect.

  1995cited by this paper
• Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial

  1993cited by this paper

• The 2023 Walter B. Cannon Award Lecture: Mechanisms Regulating Vascular Function and Blood Pressure by the PPARγ-RhoBTB1-CUL3 Pathway.

  2024cites this paper
• PPARγ Agonist Rosiglitazone and Antagonist GW9662: Antihypertensive Effects on Chronic Intermittent Hypoxia-Induced Hypertension in Rats

  2024cites this paper
• Diabetic vascular diseases: molecular mechanisms and therapeutic strategies

  2023cites this paper
• Potential Therapeutic Agents That Target ATP Binding Cassette A1 (ABCA1) Gene Expression

  2022influential citation
• Diabetes: how to manage cardiovascular risk in secondary prevention patients

  2022cites this paper
• European Stroke Organisation (ESO) guideline on pharmacological interventions for long-term secondary prevention after ischaemic stroke or transient ischaemic attack

  2022influential citation
• Stroke prevention in patients with type 2 diabetes mellitus or prediabetes: recommendations of the Spanish Society of Neurology’s Stroke Study Group

  2021cites this paper
• Role of the Peroxisome Proliferator Activated Receptors in Hypertension

  2021cites this paper
• Salt-Sensitivity of Blood Pressure and Insulin Resistance

  2021cites this paper
• Effects of pioglitazone on cardiovascular events and all-cause mortality in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.

  2021cites this paper
• Assessing the need for pioglitazone in the treatment of patients with type 2 diabetes: a meta-analysis of its risks and benefits from prospective trials

  2020cites this paper
• Uses and Limitations of the Restricted Mean Survival Time: Illustrative Examples From Cardiovascular Outcomes and Mortality Trials in Type 2 Diabetes

  2020cites this paper
• Pioglitazone Is Associated with Lower Major Adverse Cardiovascular and Cerebrovascular Events than DPP4-Inhibitors in Diabetic Patients with End-Stage Renal Disease: A Taiwan Nationwide Cohort Study, 2006–2016

  2020cites this paper
• Stroke prevention in patients with type 2 diabetes or prediabetes. Recommendations from the Cerebrovascular Diseases Study Group, Spanish Society of Neurology.

  2020cites this paper
• Pioglitazone for the primary and secondary prevention of cardiovascular and renal outcomes in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis.

  2019cites this paper
• GLUcose COntrol Safety & Efficacy in type 2 DIabetes, a systematic review and NETwork meta-analysis

  2019cites this paper
• PPARG Polymorphisms Are Associated with Unexplained Mild Vision Loss in Patients with Type 2 Diabetes Mellitus

  2019cites this paper
• Cardiac Energy Metabolism: A Potential Novel Therapeutic Target in the Treatment of Ischemic Heart Diseases

  2018cites this paper
• Cardiovascular outcomes and safety with antidiabetic drugs

  2018cites this paper
• Antidiabetic drugs for stroke prevention in patients with type-2 diabetes. The neurologist's point of view.

  2018cites this paper
• Peroxisome proliferator-activated receptor γ (PPARγ): A master gatekeeper in CNS injury and repair

  2017cites this paper
• Neurological outcomes of antidiabetic therapy: What the neurologist should know.

  2017cites this paper
• Effects of pioglitazone therapy on blood parameters, weight and BMI: a meta-analysis

  2017cites this paper
• Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis

  2017cites this paper
• Association of Nonsteroidal Anti-inflammatory Drug Use With Stroke Among Dialysis Patients

  2017cites this paper
• Pioglitazone in patients with insulin resistance after ischemic stroke or transient ischemic attack: A comment on the IRIS trial.

  2017cites this paper
• Antidiabetic drugs for stroke prevention in patients with type-2 diabetes. The neurologist's point of view.

  2017cites this paper
• Juntendo Medical Journal

  2017cites this paper
• Kardiovaskularna sigurnost oralnih antidijabetika Cardiovascular Safety of Oral Antidiabetic Drugs

  2016cites this paper
• Effects of dipeptidyl peptidase-4 inhibitors on blood pressure in patients with type 2 diabetes: A systematic review and meta-analysis

  2016cites this paper
• Effects of glucose‐lowering and multifactorial interventions on cardiovascular and mortality outcomes: a meta‐analysis of randomized control trials

  2016cites this paper
• Randomized placebo control study of insulin sensitizers (Metformin and Pioglitazone) in psoriasis patients with metabolic syndrome (Topical Treatment Cohort)

  2016cites this paper
• Cardiovascular safety of type 2 diabetes medications: Review of existing literature and clinical implications

  2016cites this paper
• Evaluating the effects of a multi-factorial quality improvement (QI) strategy targeted at primary care health care professionals on management of people with diabetes

  2016cites this paper
• Pioglitazone treatment and cardiovascular event and death in subjects with type 2 diabetes without established cardiovascular disease (JDDM 36).

  2015cites this paper
• Pioglitazone: lessons and learnings 15 years since launch and beyond

  2015cites this paper
• Pioglitazone Reduces Vascular Lipid Accumulation in Angiotensin II-Induced Hypertensive Rat.

  2015cites this paper
• Baseline diabetes as a way to predict CV outcomes in a lipid-modifying trial: a meta-analysis of 330,376 patients from 47 landmark studies

  2015cites this paper
• Effects of Pioglitazone for Secondary Stroke Prevention in Patients with Impaired Glucose Tolerance and Newly Diagnosed Diabetes: The J-SPIRIT Study.

  2015cites this paper
• Aging, the metabolic syndrome, and ischemic stroke: redefining the approach for studying the blood-brain barrier in a complex neurological disease.

  2014cites this paper
• FORMACIÓN CONTINUADA. ACTUALIZACIÓN EN MEDICINA DE FAMILIA Seguridad cardiovascular de los antidiabéticos no insulínicos. Posicionamiento científico SEMERGEN

  2014cites this paper
• Kardiovaskularna sigurnost oralnih antidijabetika Cardiovascular Safety of Oral Antidiabetic Drugs

  year unknowncites this paper